About US
Contact us
-
Limited track-and-trace moves forward in U.S.The U.S. House of Representatives has advanced one step closer to delaying the tracking of individual drug units. A House bill passed today would direct theFDAto create national standards for monitori2013/6/5
-
GSK's kidney cancer drug delays ovarian cancer relapseGlaxoSmithKline's maintenance therapy Votrient delayed disease progression in patients with advanced epithelial ovarian cancer by an average of 5.6 months following front-line chemotherapy. In a Phas2013/6/4
-
Lilly blockbuster Alimta burned by more disappointing newsThere is bad news out of ASCO for Eli Lilly's ($LLY) Alimta, its blockbuster lung cancer drug that is already under a patent assault by Teva Pharmaceutical Industries ($TEVA). Lilly today announced t2013/6/4
-
UCB sells off Rochester plant; buyer to keep 300 workersThe Belgian drugmaker UCB agreed to sell a plant in Rochester, NY, as it restructures its manufacturing operations to rely more on contract drugmakers. The sale to France-based Unither includes a 6-ye2013/5/30
-
Consumer Reports warns against fast-growing use of testosterone drugsConsumer Reports has weighed in on the rising use of testosterone drugs, which added some $2 billion to drugmakers' coffers last year. If patients listen to the magazine, pharma companies could watch2013/5/30
-
When is it fair to slap a 'pay for delay' label on a patent settlement?Are antitrust regulators unfairly targeting Big Pharma's patent settlements? As the debate rages on--and continues to spread--more experts and pharma execs are pushing back, the Financial Times repor2013/5/29
-
Valeant scoops up Bausch + Lomb as it eyes $20B in revenuesAfter rumors of balked-at price tags and an in-the-making IPO, eye-care giant Bausch + Lomb will soon belong to Valeant Pharmaceuticals ($VRX) in exchange for $8.7 billion. Under the deal, expected2013/5/29
-
AstraZeneca bets up to $443M on Omthera lipid drugPipeline-starved AstraZeneca ($AZN) snapped up Omthera ($OMTH) in a deal worth up to $443 million, on hopes for the company's omega-3 cardio drug Epanova.2013/5/28
-
Drug therapies to inhibit Dkk1 function may limit arteriosclerotic disease, study findsDrug therapies designed to inhibit endothelial Dkk1 signalling could help limit arteriosclerotic disease to prevent the thickening and hardening of the arteries.Research published online by Arterioscl2013/5/28
-
FDA responds to one small piece of Avandia criticismThe FDA yesterday responded to a Forbes op-ed from Steven Nissen, Chairman of the Department of Cardiovascular Medicine at the Cleveland Clinic, published earlier that day. In it, Nissen railed the F2013/5/27